This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue


Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.




Influenza can result in serious complications, hospitalization, and death. Annual vaccination is the primary means of preventing influenza and is recommended by the Centers for Disease Control and Prevention (CDC).6


The ACIP recommends routine influenza vaccination for all persons aged ≥6 months who do not have contraindications.2

Healthcare providers should offer vaccination by the end of October, if possible.2

Children aged 6 months through 8 years who require 2 doses should receive their first dose as soon as possible after the vaccine becomes available, and the second dose ≥4 weeks later.2

People at high risk

Although anyone can be susceptible to contracting influenza, certain groups are at increased risk of flu complications10

Children aged 6 through 59 months10

Adults aged 65 years and older10

In recent years, the CDC estimates people aged 65 years and older have accounted for9:

  • 70%-90% of seasonal flu-related deaths
  • 50%-70% of seasonal flu-related hospitalizations

Other high-risk groups10

  • Pregnant women
  • Residents of nursing homes and other long-term care facilities
  • American Indians and Alaskan Natives
  • People with certain medical conditions, including asthma, neurological and neurodevelopmental conditions, chronic lung disease, heart disease, blood disorders, endocrine disorders, kidney disorders, liver disorders, metabolic disorders, weakened immune system, people with extreme obesity (body mass index [BMI] of 40 or more), and people <19 years of age on long-term aspirin therapy.

For more information about influenza and high-risk populations, please visit the CDC.

*The CDC analyzed data sourced from the National Immunization Survey-Flu (NIS-Flu) with an unweighted sample size of 39,205 subjects aged 6 months to 4 years.8


  1. Prescribing Information for FLUARIX QUADRIVALENT.
  2. Grohskopf LA, Sokolow LZ, Broder KR, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—United States, 2018-19 influenza season. MMWR. 2018;67(3):1-20. Published August 24, 2018. February 6, 2019.
  3. American Medical Association. Current Procedural Terminology 2018: Standard Edition. Abraham M, Ahlman JT, Boudreau AJ, et al, eds. Chicago, IL: AMA Press; 2019.
  4. Hibbs BF, Moro PL, Lewis P, Miller ER, Shimabukuro TT. Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013. Vaccine. 2015;33(28):3171-3178.
  5. Institute for Safe Medication Practices. Frequently reported vaccine errors to ISMP VERP. Pharm Today. 2016;22(1):72. February 6, 2019.
  6. Centers for Disease Control and Prevention. Influenza: about flu. Reviewed September 5, 2019. Accessed November 18, 2019.
  7. Centers for Disease Control and Prevention. Estimated influenza illnesses, medical visits, hospitalizations, and deaths in the United States - 2017-2018 influenza season. Accessed February 6, 2019.
  8. Centers for Disease Control and Prevention. Estimates of flu vaccination coverage among children - United States, 2017-18 flu season. Accessed February 6, 2019.
  9. Centers for Disease Control and Prevention. People 65 years and older & influenza. Updated September 4, 2018. Accessed February 6, 2019.
  10. Centers for Disease Control and Prevention. People at high risk of developing serious flu-related complications. Updated August 27, 2018. Accessed February 6, 2019.


FLUARIX QUADRIVALENT is a vaccine indicated for active immunization for the prevention of disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FLUARIX QUADRIVALENT is approved for use in persons aged 6 months and older.

Important Safety Information for FLUARIX QUADRIVALENT

  • Do not administer FLUARIX QUADRIVALENT to anyone with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine, including egg protein, or following a previous dose of any influenza vaccine
  • If Guillain-Barré syndrome has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUARIX QUADRIVALENT should be based on careful consideration of the potential benefits and risks
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including FLUARIX QUADRIVALENT. Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope
  • If FLUARIX QUADRIVALENT is administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the immune response may be lower than in immunocompetent persons
  • In clinical trials with FLUARIX QUADRIVALENT in adults, the most common solicited local adverse reaction was pain and the most common systemic adverse reactions were muscle aches, headache, and fatigue. In children 6 through 35 months of age, the most common solicited local adverse reactions were pain and redness and the most common systemic adverse reactions were irritability, loss of appetite, and drowsiness. In children 3 through 17 years of age, the solicited local adverse reactions were pain, redness, and swelling. In children 3 through 5 years of age, the most common systemic adverse reactions were drowsiness, irritability, and loss of appetite. In children 6 through 17 years of age, the most common systemic adverse reactions were fatigue, muscle aches, headache, arthralgia, and gastrointestinal symptoms. (See Adverse Reactions section of the Prescribing Information for FLUARIX QUADRIVALENT for other potential adverse reactions and events)
  • Vaccination with FLUARIX QUADRIVALENT may not result in protection in all vaccine recipients

Please see full Prescribing Information for FLUARIX QUADRIVALENT.

All trademarks are the property of their respective owners.